A court orders Stryker to pay a $2 million to XL Insurance America, ruling that the insurer is entitled to the payment after maxing Stryker's $15 million policy limit in lawsuits over knee implants.
Orthopedics giant Stryker (NYSE:SYK) is on the hook for a $2 million payment to its insurance company after a court ruled this week that the insurer is entitled to recoup the deductible.
Stryker Corp. settles a patent infringement lawsuit filed against Johnson & Johnson's DePuy Orthopaedics division; co-defendants Wright Medical, Zimmer Holdings and Smith & Nephew move to have their cases tossed as well.
A 6th Circuit court rules that certain of Dow Corning's tissue expanders count as breast implants for the purposes of the company's $2 billion product liability settlement.
Long-embattled Dow Corning is still on the hook for complaints about 3 of its implantable tissue expanders after a 6th Circuit Court ruled that the devices count as breast implants for the purposes of a liability settlement worth more than $2 billion.
Hearing devices maker Cochlear Limited warns that Medicare's proposed rule change could limit access to certain cochlear implants.
A proposed change to Medicare's reimbursement of hearing aids could leave patients on their own when they need the a specific type of bone-anchored hearing aid implant, according to device maker Cochlear Ltd. (ASX:COH).
FDA medtech regulators decline a citizen petition to ban transvaginal mesh implants in the U.S., but "tentatively" agree that a reclassification may be in order to put the devices under more regulatory scrutiny.
FDA regulators refused this week to ban U.S. sales of pelvic mesh implants, rejecting in large part a petition filed by consumer advocacy group Public Citizen, but offered some consolation in a potential reclassification of the devices to a higher-risk category.
An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.
New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.
Abbott's MitraClip implant reduces mitral regurgitation and improves quality of life at 1 year in high-risk patients, according to new study results from the Everest II clinical trial.
High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott's (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.